Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Change in Cash (2018 - 2025)

Neurogene's Change in Cash history spans 6 years, with the latest figure at $32.8 million for Q4 2025.

  • For Q4 2025, Change in Cash fell 53.05% year-over-year to $32.8 million; the TTM value through Dec 2025 reached -$32.7 million, down 177.63%, while the annual FY2025 figure was -$32.7 million, 177.63% down from the prior year.
  • Change in Cash reached $32.8 million in Q4 2025 per NGNE's latest filing, up from $12.2 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $103.2 million in Q4 2023 to a low of -$65.8 million in Q1 2025.
  • Average Change in Cash over 3 years is $1.8 million, with a median of -$10.7 million recorded in 2023.
  • The largest YoY upside for Change in Cash was 127.46% in 2025 against a maximum downside of 3837.37% in 2025.
  • A 3-year view of Change in Cash shows it stood at $103.2 million in 2023, then tumbled by 32.19% to $70.0 million in 2024, then tumbled by 53.05% to $32.8 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Change in Cash are $32.8 million (Q4 2025), $12.2 million (Q3 2025), and -$12.0 million (Q2 2025).